NFX vs. EVG, GENF, MTFB, BSFA, DEST, VAL, ROQ, RENE, SALV, and ONC
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Evgen Pharma (EVG), Genflow Biosciences (GENF), Motif Bio (MTFB), BSF Enterprise (BSFA), Destiny Pharma (DEST), ValiRx (VAL), Roquefort Therapeutics (ROQ), ReNeuron Group (RENE), SalvaRx Group (SALV), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.
Nuformix vs.
Evgen Pharma (LON:EVG) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Nuformix has a consensus price target of GBX 293, suggesting a potential upside of 361,628.40%. Given Nuformix's stronger consensus rating and higher probable upside, analysts plainly believe Nuformix is more favorable than Evgen Pharma.
In the previous week, Evgen Pharma's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.
Nuformix's return on equity of -5.68% beat Evgen Pharma's return on equity.
Evgen Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Nuformix has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
Evgen Pharma received 124 more outperform votes than Nuformix when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 66.99% of users gave Nuformix an outperform vote.
Nuformix is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.
27.8% of Evgen Pharma shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 32.4% of Evgen Pharma shares are owned by insiders. Comparatively, 12.4% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Nuformix beats Evgen Pharma on 7 of the 13 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 5/22/2025 by MarketBeat.com Staff
